The goals of Project 3 are two-fold. The first goal is to develop in vitrolex vivo models of acute intoxication by seizurogenic chemical threat agents by applying high content, rapid throughput technology to quantitatively detect disruption of electrical and Ca^* signaling events that are known to contribute to seizure induction, severity, and promote neuronal damage. The second goal is to apply these methods to investigate existing and new therapeutic strategies for mitigating onset, progression, and severity of seizures elicited by acute intoxication with the GABA antagonist tetramethylenedisulfotetramine (TETS) and the organophosphorus (OP) cholinesterase inhibitor diisopropylfluorophosphate (DFP). The Axion multi-well multichannel electrode arrays permit unparalleled sensitivity in detecting patterns of electrical burst-spike activity in both dissociated neurons and brain slices, whereas the 96-well Tetra High Throughput Cellular Screening System (FLIPR) provides real-time assessments of spontaneous and evoked Ca oscillations. Relevant in vitro systems, including cultures enriched for primary neurons, mixed astrocyte-neuronal co-cultures, and hippocampal slices are chosen for model development because of their predictive value to Projects 1 and 2. A major outcome of the proposed studies will be to screen existing therapeutic leads and discover new therapeutic targets (with Cores A and B) that delay or mitigate triggered seizure activity and subsequent neuropathology produced by TETS and DFP. These in vitro approaches will identify the most promising therapeutic candidates and drug combinations for in vivo testing in Projects 1 and 2. Further validation and optimization of therapeutic strategies, including timing of administration, dosages, and drug combinations, will be assessed ex vivo in a reiterative process with Projects 1 and 2. The receptor based rapid-throughput approaches proposed in Project 3 will expedite more efficient formulation of optimal therapeutic strategies by Cores A and B. Moreover, the molecular and cellular mechanisms by which TETS and DFP alter the fidelity of Ca2+ signaling events to promote injurious neuronal excitability will improve our understanding of how these threat agents promote seizures and impair neural networks, providing insight into novel drug targets. Additional major milestones of the in vitro/ex vivo approach proposed in Project 3 are to accelerate: (1) Implementation of existing therapeutic agents approved for use in humans or currently undergoing clinical trials (referred to in this proposal as Tier 1), and (2) identify new receptor-targeted compounds and mixtures that improve our ability to treat acute (convulsant) and delayed (neuropathology) harm caused by exposures to seizurogenic threat agents (referred to as Tier 2 candidates).
Aim 1 : Develop rapid throughput multielectrode array (MEA) and high-resolution imaging methods to efficiently detect and discriminate threat agents that trigger electrical burst-spike activity, those that dysregulate neuronal Ca2+ signaling, and those that have both activities. 1 .a. Investigate if TETS produces electrical burst-spike activity and abnormal Ca2+ oscillations in neuronal cell cultures and/or neuron/glia co-cultures. I.b. Determine whether TETS and DFP produce similar patterns of burst-spike (epileptiform) activity in acutely dissociated hippocampal slices.
Aim 2 : Determine whether Tier 1 and novel Tier 2 therapeutic candidates, singly or in combination, ameliorate electrical and Ca2+ signaling disturbances triggered by TETS and/or DFP.
Aim 3 : Investigate if therapeutic candidates that target Ca2+ -dependent signaling events provide added neuroprotection against TETS- and DFP-triggered chronic neuropathology. 3.a. Determine whether exposures to TETS or DFP, in the presence or absence of therapeutic intervention, in vivo persistently alters the electrophysiological and Ca2+ signaling properties of hippocampal neurons and slices prepared ex vivo. 3.b. Determine whether exposures to TETS or DFP, in the presence or absence of therapeutic intervention, in vivo persistently alters the biomarkers of oxidative stress and chronic neuropathology in hippocampal neurons and slices prepared ex vivo.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Flannery, Brenna M; Silverman, Jill L; Bruun, Donald A et al. (2015) Behavioral assessment of NIH Swiss mice acutely intoxicated with tetramethylenedisulfotetramine. Neurotoxicol Teratol 47:36-45
Coleman, Nichole; Nguyen, Hai M; Cao, Zhengyu et al. (2015) The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics 12:234-49
Zhao, Chunqing; Hwang, Sung Hee; Buchholz, Bruce A et al. (2014) GABAA receptor target of tetramethylenedisulfotetramine. Proc Natl Acad Sci U S A 111:8607-12
Lee, Kin Sing Stephen; Liu, Jun-Yan; Wagner, Karen M et al. (2014) Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem 57:7016-30
Fritsch, Brita; Reis, Janine; Gasior, Maciej et al. (2014) Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. J Neurosci 34:5765-75
Kujal, Petr; ?ertíková Chábová, Vera; Škaroupková, Petra et al. (2014) Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol 41:227-37
Coleman, Nichole; Brown, Brandon M; Oliván-Viguera, Aida et al. (2014) New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol 86:342-57
Cao, Zhengyu; Cui, Yanjun; Nguyen, Hai M et al. (2014) Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Mol Pharmacol 85:630-9
Wagner, Karen; Vito, Steve; Inceoglu, Bora et al. (2014) The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling. Prostaglandins Other Lipid Mediat 113-115:2-12
Vito, Stephen T; Austin, Adam T; Banks, Christopher N et al. (2014) Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication. Toxicol Appl Pharmacol 281:185-94

Showing the most recent 10 out of 24 publications